phase readout
saveNCT05797610: A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
RECRUITINGupdated 1mo ago
community read0 votes
Sponsor: Hoffmann-La Roche. Phase: PHASE3. Conditions: Primary IgA Nephropathy
view source ↗
comments(0)
5-min edit window · permanent after that